Claims for Patent: 12,390,475

Summary for Patent: 12,390,475

Title:	Dry powder treprostinil for the treatment of pulmonary hypertension
Abstract:	A dry powder inhalation treatment for pulmonary arterial hypertension includes a dose of dry particles comprising greater than 25 micrograms of treprostinil enclosed in a capsule. The dry particles can include treprostinil, a wetting agent, a hydrophobicity modifying agent, a pH modifying agent and a buffer. A method of treating a patient having pulmonary arterial hypertension includes providing a patient a dry powder inhaler, providing the patient at least one capsule for use in the dry powder inhaler, the capsule including at least 25 micrograms of treprostinil.
Inventor(s):	Robert Frank Roscigno, Brian T. Farrer, Jacob J. Sprague, Benjamin Maynor
Assignee:	Liquidia Technologies Inc
Application Number:	US18/350,926
Patent Claims:	1. A system for administrating treprostinil or a pharmaceutically acceptable salt thereof to a patient, the system comprising: a dosage unit containing a predetermined amount of dry powder particles having a mass median aerodynamic diameter between 1 μm and 5 μm and a fine particle fraction between 82 percent and 89 percent of the predetermined amount of dry powder particles, the dry powder particles comprising: an excipient matrix; and treprostinil or a pharmaceutically acceptable salt thereof; and a dry powder inhaler comprising: a body configured to receive the dosage unit; and a mouthpiece that is moveable with respect to the body to an aligned position, wherein the dry powder inhaler allows delivery of the dry powder particles from the dosage unit through the mouthpiece to the patient via inhalation over one to two breaths when the mouthpiece is in the aligned position. 2. The system of claim 1, wherein the dry powder inhaler is actuatable by the patient to open the dosage unit while the dosage unit is received in the body to allow release of the dry powder particles from the dosage unit. 3. The system of claim 1, wherein the mouthpiece is rotatable with respect to the body. 4. The system of claim 1, wherein the system is configured to deliver from about 2.5 mg to about 5 mg of the dry powder particles to the patient per breath. 5. The system of claim 1, wherein the system is configured to deliver from about 5 mg to about 10 mg of the dry powder particles to the patient per breath. 6. The system of claim 1, wherein the system is configured to deliver from about 7.5 mg to about 15 mg of the dry powder particles to the patient per breath. 7. The system of claim 1, wherein the dosage unit contains from about 10 μg to about 220 ug treprostinil or the pharmaceutically acceptable salt thereof. 8. The system of claim 1, wherein the dry powder particles comprise about 0.53% by weight treprostinil or the pharmaceutically acceptable salt thereof. 9. The system of claim 1, wherein the dry powder particles comprise about 1.06% by weight treprostinil or the pharmaceutically acceptable salt thereof. 10. The system of claim 1, wherein the dry powder particles have a mass median aerodynamic diameter of 3 μm or less. 11. The system of claim 1, wherein the excipient matrix is formed from a dried solution comprising one or more excipients. 12. The system of claim 11, wherein the one or more excipients comprises one or more of a bulking agent, a wetting agent, a hydrophobicity modifier, a pH modifier, and a buffer. 13. The system of claim 12, wherein the one or more excipients comprises a bulking agent and a pH modifier. 14. The system of claim 1, wherein the dry powder particles are dried to less than 5 percent water content. 15. The system of claim 1, wherein the dosage unit comprises a capsule. 16. The system of claim 1, wherein the treprostinil or a pharmaceutically acceptable salt thereof becomes pharmaceutically available in less than 10 seconds upon delivery to the patient via inhalation. 17. The system of claim 16, wherein the treprostinil or a pharmaceutically acceptable salt thereof becomes pharmaceutically available in less than 5 seconds upon delivery to the patient via inhalation. 18. The system of claim 16, wherein the treprostinil or a pharmaceutically acceptable salt thereof becomes pharmaceutically available in less than 1 second upon delivery to the patient via inhalation. 19. The system of claim 1, further comprising a second dosage unit receivable in the body of the dry powder inhaler, the second dosage unit containing a second predetermined amount of the dry powder particles. 20. The system of claim 19, wherein each of the dosage unit and the second dosage unit contains from about 10 μg to about 220 μg treprostinil or the pharmaceutically acceptable salt thereof.